Please assess the completion status of the following clinical trial:

Trial Title: Myfortic - Treatment for Extensive cGvHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 - 60~* Any primary diagnosis requiring treatment by hematopoietic stem cell transplantation~* Recipient of a single allogeneic stem cell transplant (bone marrow or peripheral blood stem cells, or cord blood) minimum 80 days ago~* Received a graft from a related or an unrelated donor~* Conditioning regimen: Myeloablative or non-myeloablative~* Patients suffering a first episode of extensive chronic GvHD, without recurrent disease~* The diagnosis of chronic GvHD requires the following:~  * Distinction from acute GvHD~ * Presence of at least one diagnostic clinical sign of chronic GvHD or presence of at least one distinctive sign confirmed by pertinent biopsy or other relevant diagnostic tests~ * Exclusion of other possible diagnoses~* Receiving a standard prophylaxis regimen for acute GvHD: CsA plus methotrexate, or CSA+MMF for NMA, or a T-cell depleted transplant~* Patient gives written informed consent prior to randomization~Exclusion Criteria:~* Patient age less than 18 years or over 60 years.~* GvHD prophylaxis by tacrolimus plus methotrexate~* Delayed onset acute GvHD following NMA or DLI~* Second allogeneic stem cell transplant~* Not the first episode of chronic GvHD needing systemic immunosuppressive therapy.~* Limited chronic GvHD (Seattle criteria, see Appendix 1)~* Uncontrolled systemic infection which in the opinion of the investigator is associated with an increased risk of the patient's death within 1 week of randomization~* In the opinion of the investigator, if the patient has significant medical or psychosocial problems or unstable disease status~* Pregnant or lactating females~* Known hypersensitivity to mycophenolic acid

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Myfortic (Type: ACTIVE_COMPARATOR): Patients in this arm will receive Myfortic + Prednisone + Cyclosporine
- Standard Care/ Placebo (Type: OTHER): In this arm patients will receive Prednisone + Cyclosporine + Placebo or Prednisone + Cyclosporine

Based on this trial design, predict the completion outcome and termination type (if applicable).